Genelux Announces Oral Plenary Presentation of VIRO-15 Phase 2 Trial Data at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society
- Thursday, September 10, 2020, 7:09
- Finance
- Add a comment
SAN DIEGO, Sept. 10, 2020 /PRNewswire/ — Genelux Corporation, a privately-held biopharmaceutical company, today announced that the abstract covering data from the VIRO-15 Phase 2 trial (NCT02759588) has been accepted for an Oral Plenary Session at the 2020 xDigital Global Annual Meeting…
About the Author
adminasapcorp has written 41555 stories on this site.